Gabelli analyst Kevin Kendra upgraded Teva Pharma (NYSE: TEVA) from Hold to Buy.The analyst comments "We are raising our recommendation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE